4 May 2011
Instem Life Science Systems plc
("Instem", the "Company" or the "Group")
Posting of Annual Report and Accounts
Notice of Annual General Meeting
For further information, please contact:
Instem Life Science Systems plc |
+44 (0) 1785 825600 |
Phil Reason, CEO |
|
Jim McLauchlan, CFO |
|
|
|
Brewin Dolphin - Financial Advisor, Broker & NOMAD |
+44 (0) 845 213 4730 |
Mark Brady |
|
Sean Wyndham-Quin |
|
|
|
Threadneedle Communications |
+44 (0) 20 7653 9850 |
Caroline Evans-Jones |
|
Fiona Conroy |
|
|
|
About Instem Life Science Systems plc
Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.
To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.